COVID-19 infection in patients with acute leukemia; Istanbul experience.

Autor:	Buyuktas D; Department of Hematology, School of Medicine, Koc University Istanbul, Turkey., Acar K; Division of Hematology and Bone Marrow Transplantation Unit, Department of Internal Medicine and Hematology, Bahcelievler Medical Park Hospital Istanbul, Turkey., Sucak G; Division of Hematology and Bone Marrow Transplantation Unit, Department of Internal Medicine and Hematology, Bahcelievler Medical Park Hospital Istanbul, Turkey., Toptas T; Department of Hematology, Marmara University Medical Faculty Istanbul, Turkey., Kapucu I; Department of Hematology, School of Medicine, Koc University Istanbul, Turkey., Bekoz H; Division of Hematology, Department of Internal Medicine, Medipol University Istanbul, Turkey., Erdem S; Division of Hematology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University Istanbul, Turkey., Nalcaci M; Division of Hematology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University Istanbul, Turkey., Atalay F; Department of Hematology, Başkent University Istanbul Hospital Istanbul, Turkey., Akay MO; Department of Hematology, School of Medicine, Koc University Istanbul, Turkey., Ferhanoglu B; Department of Hematology, School of Medicine, Koc University Istanbul, Turkey.
Jazyk:	angličtina
Zdroj:	American journal of blood research [Am J Blood Res] 2021 Aug 15; Vol. 11 (4), pp. 427-437. Date of Electronic Publication: 2021 Aug 15 (Print Publication: 2021).
Abstrakt:	Coronavirus disease 2019 (COVID-19) has led to a global pandemic that has also challenged the management of various other life-threatening conditions, such as malignant disorders. In this study, we present the clinical features and treatment outcomes of twenty-seven COVID-19 positive patients with leukemia across seven different centers in Istanbul. From March 1st to December 31st 2020, 116 patients were diagnosed with acute leukemia. Thirty-two cases with acute lymphocytic leukemia (ALL), 82 cases with acute myeloid leukemia (AML), and 2 cases with mixed phenotype acute leukemia (MPAL) were identified. Of the 27 patients with the COVID-19 infection, seven patients had ALL, 19 patients had AML and one patient had MPAL. The mortality rate was 37% among the patients with AML, whereas there were no deaths in the ALL group. The mortality rate of AML patients with the COVID-19 infection was higher compared to cases without the infection (P<0.05). We could not detect any significant difference in the ALL cohort. This study, which includes one of the largest acute leukemia series in literature proved that acute myeloid leukemia patients with the COVID-19 infection have worse outcomes than patients without the infection. The high mortality among patients with acute leukemias hospitalized with COVID-19 highlight the need for aggressive infection prevention, increased surveillance and protective isolation and even modification of the therapy, in case of minimal residual disease (MRD) negativity. Competing Interests: None. (AJBR Copyright © 2021.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu